Attention Bias Modification Training for Social Phobia (ABMSP)

Status Recruiting

Clinical Trial Summary

Attentional bias has primarily been investigated as a primary cognitive etiology of social anxiety symptoms. Previous research has found that individuals with high social anxiety showed facilitated attentional engagement to threat stimuli or delayed disengagement of attention from threat. Attentional Bias Modification Training (ABMT) was developed through applying the attentional mechanism in social anxiety. During ABMT, participants are deliberately induced to shift their attention away from threat stimuli and toward neutral stimuli. Despite its proven effectiveness, a recent meta-study found that the effect size of ABMT is significant but too small. As a result, the current study focuses on improving the existing ABMT by incorporating integrative factors into attention training. The current study aims to integrate bottom-up and top-down cognitive processes in ABMT. Participants will be randomly assigned to one of two conditions (active or placebo training) and will complete the ABMT for three weeks. The ABMT's efficacy will be assessed by comparing pre- and post-training measures.

Clinical Trial Description

Individuals with at least mild level of social anxiety symptoms will be invited to the current study. Participants will be randomly assigned to one of the two attention training conditions: a Integrated Attentional Bias Modification (I-ABM) training or placebo training (PLT). Before and after the training, participants will complete computerized tasks (e.g., attention network task, dot-probe task) and self-report questionnaires. The basic design of I-ABM training will follow the dot-probe task, which will ask participants to swipe or tap on the probe in the correct direction. The I-ABM training aims to shift attention away from threatening stimuli or improve the inhibitory control ability. The PLT training will have the same basic design, but this will not include therapeutic components. Participants will complete the training three times per week for three weeks (a total of 9 training sessions), and there will be post-training and a 2-week follow-up assessment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06054386
Study type	Interventional
Source	University of Wisconsin, Milwaukee
Contact	Yourim Kim, M.A.
Phone	414-251-5124
Email	yourim@uwm.edu
Status	Recruiting
Phase	N/A
Start date	April 7, 2022
Completion date	August 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06274112` - Using TMS to Understand Neural Processes of Social Motivation	N/A
Completed	`NCT02554929` - Treatment of Social Anxiety Disorder and Selective Mutism	N/A
Completed	`NCT00684541` - Interpretation Modification Program for Social Phobia	N/A
Completed	`NCT00684320` - Attention Disengagement Training for Social Phobia	N/A
Completed	`NCT03247075` - Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT	N/A
Completed	`NCT02811458` - Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders	N/A
Withdrawn	`NCT04622930` - Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD)	N/A
Active, not recruiting	`NCT05018312` - Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety	N/A
Active, not recruiting	`NCT05124639` - Clinical Trial of a Group Self-management Support Program for Anxiety Disorders	N/A
Completed	`NCT05858294` - The Safety, Acceptability and Efficacy of Alena	N/A
Active, not recruiting	`NCT05600114` - Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder	Phase 2
Not yet recruiting	`NCT06081348` - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders	Phase 2
Not yet recruiting	`NCT02924610` - Brief Intervention to Reduce Fear	Phase 4
Active, not recruiting	`NCT02592564` - Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder	N/A
Recruiting	`NCT02305537` - Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment	N/A
Terminated	`NCT03764644` - Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders	N/A
Unknown status	`NCT01712321` - Study of Vilazodone to Treat Social Anxiety Disorder	N/A
Completed	`NCT01320800` - CBT for Social Anxiety Disorder Delivered by School Counselors	Phase 2
Completed	`NCT00485615` - An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia	Phase 2
Completed	`NCT00773162` - Flushing in Social Anxiety Disorder on Seroquel	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.